MBIO: the cashflow

MyFinsight

The latest financial statement is for the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-468	-915
Issuance of common shares - equity fee on equity offerings to fortress biotech	179	216
Stock-based compensation expenses	23	83
Depreciation expense	0	34
Amortization of operating lease right-of-use assets	0	7
Settlement of payables	577	796
Loss on disposal of property and equipment	0	0
Asset impairment	0	0
Gain on lease termination	0	394
Prepaid expenses and other assets	-12	-28
Other receivables	0	-435
Accounts payable and accrued expenses	-12	-1,190
Payable and accrued expenses - related party	25	-163
Lease liabilities	0	73
Net cash used in operating activities	-818	-2,728
Proceeds from the sale of property and equipment	0	1,165
Net cash from investing activities	0	1,165
Proceeds from issuance of common shares, net of offering costs - equity offering	0	6,782
Proceeds from issuance of common shares, net of offering costs - at-the-market offering	0	599
Proceeds from warrant exercises	7,145	0
Proceeds from issuance of common shares under espp	0	0
Net cash provided by financing activities	7,145	7,381
Net change in cash, cash equivalents and restricted cash	6,327	5,818
Cash and cash equivalents at beginning of period	6,839	-
Cash and cash equivalents at end of period	18,984	-

Unit: Thousand (K) dollars